Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Norian Corporation is a medical technology company specializing in the development of injectable calcium phosphate bone cements for orthopedic and craniofacial applications. The company is best known for its Norian SRS (Skeletal Repair System), a biocompatible material that chemically transforms into a carbonated apatite similar to natural bone mineral. These products are designed to provide immediate structural support and are gradually remodeled and replaced by the patient's own bone over time. Originally founded in 1987, Norian was acquired by Synthes in 1999 and subsequently became part of DePuy Synthes following Johnson & Johnson's acquisition of Synthes. The technology represents a significant advancement in biomaterials, offering an alternative to traditional bone grafts and metallic fixation in specific clinical scenarios. Despite its clinical success, the company faced significant legal challenges in the 2010s regarding the off-label use of its products in spinal surgeries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Norian.